Compare Stocks: PHAR, VCYT, QURE, and CLDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$40.57 +0.5%	$37.89	$21.33 ▼ $45.14	$3.19B	0.87	963,145 shs	416,888 shs
PHAR Pharming Group	$11.46 -3.3%	$12.59	$9.62 ▼ $21.34	$811.14M	-0.01	19,227 shs	23,168 shs
QURE uniQure	$47.46 -1.9%	$43.78	$8.73 ▼ $71.50	$3.29B	0.93	2.42 million shs	920,824 shs
VCYT Veracyte	$41.47 -2.0%	$52.57	$28.25 ▼ $60.91	$3.33B	1.95	1.09 million shs	1.17 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	0.00%	-3.74%	+14.46%	+31.40%	+79.79%
PHAR Pharming Group	0.00%	+1.11%	-5.99%	-5.95%	-13.50%
QURE uniQure	0.00%	-0.51%	+24.12%	+99.96%	+208.09%
VCYT Veracyte	0.00%	+2.57%	-25.26%	-6.04%	+36.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$40.57 +0.5%	$37.89	$21.33 ▼ $45.14	$3.19B	0.87	963,145 shs	416,888 shs
PHAR Pharming Group	$11.46 -3.3%	$12.59	$9.62 ▼ $21.34	$811.14M	-0.01	19,227 shs	23,168 shs
QURE uniQure	$47.46 -1.9%	$43.78	$8.73 ▼ $71.50	$3.29B	0.93	2.42 million shs	920,824 shs
VCYT Veracyte	$41.47 -2.0%	$52.57	$28.25 ▼ $60.91	$3.33B	1.95	1.09 million shs	1.17 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	0.00%	-3.74%	+14.46%	+31.40%	+79.79%
PHAR Pharming Group	0.00%	+1.11%	-5.99%	-5.95%	-13.50%
QURE uniQure	0.00%	-0.51%	+24.12%	+99.96%	+208.09%
VCYT Veracyte	0.00%	+2.57%	-25.26%	-6.04%	+36.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.85	Moderate Buy	$56.08	38.24% Upside
PHAR Pharming Group	2.20	Hold	$38.67	237.41% Upside
QURE uniQure	2.71	Moderate Buy	$65.00	36.96% Upside
VCYT Veracyte	2.82	Moderate Buy	$54.33	31.02% Upside

Current Analyst Ratings Breakdown

Latest PHAR, VCYT, QURE, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	VCYT Veracyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2026	PHAR Pharming Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00
8/4/2026	VCYT Veracyte	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$66.00 ➝ $54.00
8/4/2026	VCYT Veracyte	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$68.00 ➝ $55.00
8/4/2026	VCYT Veracyte	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underweight	$47.00 ➝ $44.00
8/3/2026	VCYT Veracyte	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$60.00 ➝ $50.00
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
7/31/2026	VCYT Veracyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$57.00 ➝ $69.00

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$158K	20,164.32	N/A	N/A	$7.93 per share	5.12
PHAR Pharming Group	$376.13M	2.16	$0.19 per share	59.09	$3.95 per share	2.90
QURE uniQure	$16.10M	204.49	N/A	N/A	$3.19 per share	14.88
VCYT Veracyte	$561.90M	5.93	$1.46 per share	28.41	$16.57 per share	2.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	95.50	38.20	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)
VCYT Veracyte	$66.35M	$1.41	29.41	26.93	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest PHAR, VCYT, QURE, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	11.82	11.82
PHAR Pharming Group	0.34	3.01	2.31
QURE uniQure	0.15	10.01	10.01
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
PHAR Pharming Group	0.03%
QURE uniQure	78.83%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	5.20%
PHAR Pharming Group	2.07%
QURE uniQure	4.65%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	78.53 million	74.45 million	Optionable
PHAR Pharming Group	280	70.78 million	69.31 million	Not Optionable
QURE uniQure	500	69.37 million	66.14 million	Optionable
VCYT Veracyte	790	80.39 million	79.11 million	Optionable

PHAR, VCYT, QURE, and CLDX Headlines

Recent News About These Companies

74,576 Shares in Veracyte, Inc. $VCYT Acquired by Globeflex Capital L P

August 24 at 4:31 AM | marketbeat.com

BlackRock Inc. Acquires New Position in Veracyte, Inc. $VCYT

August 23 at 3:28 AM | marketbeat.com

1,431,596 Shares in Veracyte, Inc. $VCYT Bought by William Blair Investment Management LLC

August 22 at 6:47 AM | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of "Moderate Buy" by Brokerages

August 22 at 2:15 AM | americanbankingnews.com

Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from Brokerages

August 22 at 2:13 AM | marketbeat.com

Virtus Advisers LLC Purchases New Shares in Veracyte, Inc. $VCYT

August 21 at 6:31 AM | marketbeat.com

Great Lakes Advisors LLC Invests $3.85 Million in Veracyte, Inc. $VCYT

August 21 at 4:00 AM | marketbeat.com

Lisanti Capital Growth LLC Purchases Shares of 63,400 Veracyte, Inc. $VCYT

August 20, 2026 | marketbeat.com

Head-To-Head Review: CAMP4 Therapeutics (NASDAQ:CAMP) & Veracyte (NASDAQ:VCYT)

August 20, 2026 | americanbankingnews.com

Summit Creek Advisors LLC Takes Position in Veracyte, Inc. $VCYT

August 19, 2026 | marketbeat.com

Rice Hall James & Associates LLC Invests $5.61 Million in Veracyte, Inc. $VCYT

August 18, 2026 | marketbeat.com

Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround

August 17, 2026 | zacks.com

Zacks Research Upgrades Veracyte (NASDAQ:VCYT) to Strong-Buy

August 13, 2026 | marketbeat.com

Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT

August 13, 2026 | marketbeat.com

Amundi Sells 116,588 Shares of Veracyte, Inc. $VCYT

August 12, 2026 | marketbeat.com

Veracyte: Diagnostics With Favorable Economics

August 10, 2026 | seekingalpha.com

Veracyte: Core Growth Funds Prosigna And TrueMRD

August 9, 2026 | seekingalpha.com

Royal Bank of Canada Grows Stock Holdings in Veracyte, Inc. $VCYT

August 7, 2026 | marketbeat.com

Veracyte, Inc. $VCYT Shares Sold by Janus Henderson Group PLC

August 7, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Growth Story Gains Fresh Market Attention

August 6, 2026 | kalkinemedia.comK

Empowered Funds LLC Buys 68,171 Shares of Veracyte, Inc. $VCYT

August 6, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PHAR, VCYT, QURE, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$40.57 +0.19 (+0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$40.57 0.00 (0.00%)

As of 04:20 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Pharming Group NASDAQ:PHAR

$11.46 -0.39 (-3.29%)

Closing price 03:59 PM Eastern

Extended Trading

$11.46 0.00 (0.00%)

As of 04:10 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

uniQure NASDAQ:QURE

$47.46 -0.91 (-1.88%)

Closing price 04:00 PM Eastern

Extended Trading

$47.49 +0.03 (+0.06%)

As of 06:49 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Veracyte NASDAQ:VCYT

$41.47 -0.84 (-1.99%)

Closing price 04:00 PM Eastern

Extended Trading

$41.57 +0.10 (+0.24%)

As of 06:45 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAR, VCYT, QURE, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAR, VCYT, QURE, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAR, VCYT, QURE, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHAR, VCYT, QURE, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

Pharming Group NASDAQ:PHAR

uniQure NASDAQ:QURE

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHAR, VCYT, QURE, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHAR, VCYT, QURE, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHAR, VCYT, QURE, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PHAR, VCYT, QURE, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

Pharming Group NASDAQ:PHAR

uniQure NASDAQ:QURE

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools